Latest Insider Transactions at Cortexyme, Inc. (CRTX)
This section provides a real-time view of insider transactions for Cortexyme, Inc. (CRTX). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Cortexyme, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Cortexyme, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Oct 05
2021
|
Christopher P. Lowe Interim CEO, COO & CFO |
SELL
Open market or private sale
|
Direct |
4,963
-7.64%
|
$486,374
$98.5 P/Share
|
|
Oct 05
2021
|
Christopher P. Lowe Interim CEO, COO & CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
4,963
+7.1%
|
$268,002
$54.85 P/Share
|
|
Aug 17
2021
|
Christopher P. Lowe Interim CEO, COO & CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
30,000
+33.33%
|
$60,000
$2.23 P/Share
|
|
Aug 16
2021
|
Christopher P. Lowe Interim CEO, COO & CFO |
SELL
Open market or private sale
|
Direct |
22,000
-10.22%
|
$2,112,000
$96.35 P/Share
|
|
Aug 16
2021
|
Christopher P. Lowe Interim CEO, COO & CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
22,000
+29.73%
|
$44,000
$2.23 P/Share
|
|
Aug 16
2021
|
Margaret Mc Loughlin |
SELL
Open market or private sale
|
Direct |
6,000
-70.28%
|
$576,000
$96.62 P/Share
|
|
Aug 16
2021
|
Margaret Mc Loughlin |
BUY
Exercise of conversion of derivative security
|
Direct |
6,000
+50.0%
|
$102,000
$17.0 P/Share
|
|
Aug 10
2021
|
Michael J. Detke Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
10,000
-100.0%
|
$1,000,000
$100.0 P/Share
|
|
Aug 10
2021
|
Michael J. Detke Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+50.0%
|
$20,000
$2.23 P/Share
|
|
Jul 07
2021
|
Michael J. Detke Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
17,400
-52.94%
|
$957,000
$55.25 P/Share
|
|
Jul 07
2021
|
Michael J. Detke Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
17,400
+50.0%
|
$34,800
$2.23 P/Share
|
|
Jul 06
2021
|
Michael J. Detke Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
40,861
-91.9%
|
$2,206,494
$54.12 P/Share
|
|
Jul 06
2021
|
Michael J. Detke Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
12,600
+23.57%
|
$25,200
$2.23 P/Share
|
|
Jun 30
2021
|
Christopher P. Lowe Interim CEO, COO & CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
30,000
+50.0%
|
$60,000
$2.23 P/Share
|
|
Jun 28
2021
|
Christopher P. Lowe Interim CEO, COO & CFO |
SELL
Open market or private sale
|
Direct |
20,000
-69.05%
|
$1,080,000
$54.7 P/Share
|
|
Jun 28
2021
|
Christopher P. Lowe Interim CEO, COO & CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
20,000
+50.0%
|
$40,000
$2.23 P/Share
|
|
Jun 28
2021
|
Margaret Mc Loughlin |
SELL
Open market or private sale
|
Direct |
550
-69.26%
|
$30,250
$55.26 P/Share
|
|
May 10
2021
|
Casey Lynch Chief Executive Officer |
SELL
Open market or private sale
|
Indirect |
30,000
-0.75%
|
$1,050,000
$35.3 P/Share
|
|
Mar 24
2021
|
David Lamond |
BUY
Open market or private purchase
|
Indirect |
50,000
+2.64%
|
$1,650,000
$33.77 P/Share
|
|
Mar 22
2021
|
Casey Lynch Chief Executive Officer |
SELL
Open market or private sale
|
Indirect |
30,000
-0.73%
|
$1,080,000
$36.03 P/Share
|
|
Mar 04
2021
|
David Lamond |
BUY
Bona fide gift
|
Indirect |
1,534,720
+50.0%
|
-
|
|
Mar 04
2021
|
David Lamond |
BUY
Open market or private purchase
|
Indirect |
50,000
+0.7%
|
$1,750,000
$35.62 P/Share
|
|
Feb 03
2021
|
Casey Lynch Chief Executive Officer |
SELL
Open market or private sale
|
Indirect |
20,000
-0.21%
|
$820,000
$41.85 P/Share
|
|
Feb 02
2021
|
Casey Lynch Chief Executive Officer |
SELL
Open market or private sale
|
Indirect |
20,000
-0.93%
|
$720,000
$36.39 P/Share
|
|
Feb 01
2021
|
Casey Lynch Chief Executive Officer |
SELL
Open market or private sale
|
Indirect |
20,000
-0.31%
|
$720,000
$36.99 P/Share
|
|
Dec 14
2020
|
Leslie Holsinger EVP, Preclinical Development |
SELL
Open market or private sale
|
Direct |
40,000
-33.15%
|
$1,240,000
$31.14 P/Share
|
|
Dec 14
2020
|
Leslie Holsinger EVP, Preclinical Development |
BUY
Exercise of conversion of derivative security
|
Direct |
40,000
+47.9%
|
$0
$0.27 P/Share
|
|
Dec 10
2020
|
Leslie Holsinger EVP, Preclinical Development |
BUY
Exercise of conversion of derivative security
|
Direct |
3,500
+50.0%
|
$0
$0.27 P/Share
|
|
Jun 12
2020
|
Epiq Capital Group, LLC |
BUY
Open market or private purchase
|
Indirect |
2,440
+0.09%
|
$107,360
$44.06 P/Share
|
|
Jun 11
2020
|
Epiq Capital Group, LLC |
BUY
Open market or private purchase
|
Indirect |
6,600
+0.23%
|
$290,400
$44.32 P/Share
|
|
Jun 03
2020
|
Pfizer Inc > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
370,000
-11.38%
|
$14,800,000
$40.18 P/Share
|
|
May 22
2020
|
Epiq Capital Group, LLC |
BUY
Open market or private purchase
|
Indirect |
2,085
+0.07%
|
$114,675
$55.9 P/Share
|
|
May 21
2020
|
Epiq Capital Group, LLC |
BUY
Open market or private purchase
|
Indirect |
520
+0.02%
|
$28,600
$55.8 P/Share
|
|
May 20
2020
|
Epiq Capital Group, LLC |
BUY
Open market or private purchase
|
Indirect |
6,085
+0.11%
|
$346,845
$57.61 P/Share
|
|
Jan 29
2020
|
Epiq Capital Group, LLC |
SELL
Other acquisition or disposition
|
Indirect |
4,338
-0.15%
|
$234,252
$54.3 P/Share
|
|
Aug 21
2019
|
Epiq Capital Group, LLC |
BUY
Open market or private purchase
|
Direct |
1,635
+0.06%
|
$39,240
$24.87 P/Share
|
|
Aug 21
2019
|
Epiq Capital Group, LLC |
BUY
Open market or private purchase
|
Indirect |
420
+0.01%
|
$10,080
$24.87 P/Share
|
|
Aug 20
2019
|
Epiq Capital Group, LLC |
BUY
Open market or private purchase
|
Direct |
2,310
+0.08%
|
$57,750
$25.69 P/Share
|
|
Aug 20
2019
|
Epiq Capital Group, LLC |
BUY
Open market or private purchase
|
Indirect |
600
+0.02%
|
$15,000
$25.69 P/Share
|
|
Aug 19
2019
|
Epiq Capital Group, LLC |
BUY
Open market or private purchase
|
Indirect |
2,100
+0.07%
|
$54,600
$26.5 P/Share
|
|
Aug 16
2019
|
Epiq Capital Group, LLC |
BUY
Open market or private purchase
|
Indirect |
700
+0.02%
|
$18,200
$26.37 P/Share
|
|
May 13
2019
|
Pfizer Inc > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
50,000
+1.52%
|
$850,000
$17.0 P/Share
|
|
May 13
2019
|
Pfizer Inc > 10% Shareholder |
BUY
Conversion of derivative security
|
Direct |
3,199,973
+24.68%
|
-
|
|
May 10
2019
|
Epiq Capital Group, LLC |
BUY
Open market or private purchase
|
Indirect |
4,250
+0.08%
|
$114,750
$27.32 P/Share
|
|
May 10
2019
|
Epiq Capital Group, LLC |
BUY
Open market or private purchase
|
Direct |
4,350
+0.15%
|
$113,100
$26.41 P/Share
|